Table 1.
Clinical Characteristics of Patients With Bone Metastases With and Without SREs
| Patients With SREs (n = 48) | Patients Without SREs (n = 19) | P Value | |
|---|---|---|---|
| Median (range) age, y | 50 (15–79) | 50 (9–70) | NS |
| Sex, n (%) | |||
| Female | 19 (40) | 8 (42) | NS |
| Male | 29 (60) | 11 (58) | |
| Median (range) primary tumor size, cm | 7.7 (1.1–17.3) | 10 (2.5–24) | NS |
| Type of metastases, n (%) | |||
| Only BM | 15 (31) | 3 (16) | NS |
| BM and nonosseous metastases | 33 (69) | 16 (84) | |
| Had SDHB genetic testing, n (%) | 10 (21) | 11 (58) | NS |
| SDHB-positive, n (%) | 5 (50) | 4 (36) | |
| Systemic treatment, n (%)a | <.0001 | ||
| Chemotherapy | 4 (8) | 7 (37) | |
| MIBG | 0 | 1 (5) | |
| Chemotherapy + MIBG | 0 | 1 (5) | |
| MIBG + bisphosphonates | 0 | 2 (11) | |
| Chemotherapy + MIBG + bisphosphonates | 4 (8) | 1 (5) | |
| Bisphosphonates | 2 (4) | 1 (5) | |
| Chemotherapy + bisphosphonates | 0 | 1 (5) | |
| TKI + denosumab | 0 | 1 (5) | |
| Died before treatment | 0 | 4 (21) | |
| No systemic treatment | 38 (79) | ||
| Functioning tumors, n (%)c | NS | ||
| ≥4 times higher | 23/34 (68)b | 12/17 (71)b | |
| 1–3 times higher | 6/34 (18)b | 2/17 (12)b | |
| Nonfunctioning tumors | 5/34 (15)b | 3/17 (18)b | |
| Status at last follow-up, n (%) | NS | ||
| Alive | 10 (22) | 5 (26) | |
| Deceased | 38 (79) | 14 (74) |
Abbreviations: NS, nonsignificant; TKI, Tyrosine kinase inhibitors.
a
For patients with SREs: systemic treatment at any time before SRE diagnosis.
b
Available samples.
c
Urine/plasma catecholamine or metanephrines 4-fold upper normal limit.